Expression system

US9994622B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9994622-B2
Application numberUS-201615210245-A
CountryUS
Kind codeB2
Filing dateJul 14, 2016
Priority dateOct 8, 2009
Publication dateJun 12, 2018
Grant dateJun 12, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.

First claim

Opening claim text (preview).

The invention claimed is: 1. A process for periplasmic expression of a bacterial toxin, the process comprising growing a culture of Escherichia coli ( E. coli ) host cells containing a polynucleotide comprising: (a) a 3′ toxin sequence encoding a mature bacterial toxin polypeptide having an amino acid sequence at least 90% identical to SEQ ID NO:32, and (b) a 5′ signal sequence encoding a signal peptide, wherein the signal peptide directs transport of said bacterial toxin polypeptide to the bacterial periplasm when expressed in said host cell, and wherein the 5′ signal sequence is not derived from Corynebacterium diphtheriae ( C. diphtheriae ); and inducing expression of said polynucleotide such that said bacterial toxin polypeptide is expressed periplasmically, wherein the process is carried out in a fermentor. 2. The process of claim 1 wherein the 3′ toxin sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 32. 3. The process of claim 1 wherein the 3′ toxin sequence comprises SEQ ID NO: 31. 4. The process of claim 1 wherein the 3′ toxin sequence encodes CRM197. 5. The process of claim 1 wherein the 3′ toxin sequence encodes a polypeptide having at least 95% sequence identity to SEQ ID NO: 32. 6. The process of claim 1 wherein the polynucleotide encodes a polypeptide comprising any one of SEQ ID NOs: 33-45. 7. The process of claim 1 wherein the 5′ signal sequence is directly 5′ of the 3′ toxin sequence of the polynucleotide. 8. The process of claim 1 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence selected from: (a) SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26; (b) variants of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26 containing 1, 2 or 3 point mutations, insertions or deletions, which variants are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell, and (c) fragments of at least 10 amino acids of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26, which fragments are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell. 9. The process of claim 1 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence selected from: (i) SEQ ID NO: 24; (ii) variants of SEQ ID NO: 24 containing 1, 2 or 3 point mutations, insertions or deletions, which variants are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell; and (iii) fragments of at least 10 amino acids of SEQ ID NO: 24, which fragments are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell. 10. The process of claim 1 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. 11. The process of claim 1 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence of SEQ ID NO: 24. 12. The process of claim 1 wherein the 5′ signal sequence comprises a nucleic acid sequence selected from SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25. 13. The process of claim 1 wherein the 5′ signal sequence comprises SEQ ID NO: 23. 14. A process for periplasmic expression of a bacterial toxin, the process comprising growing a culture of E. coli host cells containing a polynucleotide comprising: (a) a 3′ toxin sequence encoding a mature bacterial toxin polypeptide having an amino acid sequence at least 90% identical to SEQ ID NO:32, and (b) a 5′ signal sequence encoding a signal peptide, wherein the signal peptide directs transport of said bacterial toxin polypeptide to the bacterial periplasm when expressed in said host cell, and wherein the 5′ signal sequence is not derived from C. diphtheriae , and wherein the signal peptide has an amino acid sequence selected from: (i) SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26; (ii) variants of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26 containing 1, 2 or 3 point mutations, insertions or deletions, which variants are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell, and (iii) fragments of at least 10 amino acids of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26, which fragments are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell, and inducing expression of said polynucleotide such that said bacterial toxin polypeptide is expressed periplasmically, wherein the process is carried out in a fermentor. 15. The process of claim 14 wherein the 3′ toxin sequence encodes a polypeptide having the amino acid sequence of SEQ ID NO: 32. 16. The process of claim 14 wherein the 3′ toxin sequence comprises SEQ ID NO:31. 17. The process of claim 14 wherein the 3′ toxin sequence encodes CRM197. 18. The process of claim 14 wherein the 3′ toxin sequence encodes a polypeptide having at least 95% sequence identity to SEQ ID NO: 32. 19. The process of claim 14 wherein the polynucleotide encodes a polypeptide comprising any one of SEQ ID NOs: 33-45. 20. The process of claim 14 wherein the 5′ signal sequence is directly 5′ of the 3′ toxin sequence of the polynucleotide. 21. The process of claim 14 , wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence selected from: (a) SEQ ID NO: 24; (b) variants of SEQ ID NO: 24, varying from the corresponding sequence by 1, 2 or 3 point mutations, amino acid insertions or amino acid deletions, which variants are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell; and (c) fragments of at least 10 amino acids of SEQ ID NO: 24, which fragments are capable of directing transport of said bacterial toxin polypeptide to the periplasm of said bacterial host cell. 22. The process of claim 14 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. 23. The process of claim 14 wherein the 5′ signal sequence encodes a signal peptide having an amino acid sequence of SEQ ID NO: 24. 24. The process of claim 14 wherein the 5′ signal sequence comprises a nucleic acid sequence selected from SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25. 25. The process of claim 14 wherein the 5′ signal sequence comprises SEQ ID NO: 23. 26. The process of claim 1 comprising a further step (c) of harvesting cell paste from the culture and purifying the bacterial toxin polypeptide. 27. The process of claim 26 further comprising a step of mixing the purified bacterial toxin polypeptide with a pharmaceutically acceptable excipient. 28. The process of claim 14 comprising a further step (c) of harvesting cell paste from the culture and purifying the bacterial toxin. 29. The process of claim 28 further comprising a step of mixing the purified bacterial toxin polypeptide with a pharmaceutically acceptable excipient.

Assignees

Inventors

Classifications

  • Antibacterial agents · CPC title

  • containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved · CPC title

  • NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36) · CPC title

  • C07K14/34Primary

    from Corynebacterium (G) · CPC title

  • Pentosyltransferases (2.4.2) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9994622B2 cover?
Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.
Who is the assignee on this patent?
Glaxosmithkline Biologicals Sa
What technology area does this patent fall under?
Primary CPC classification C07K14/34. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).